18F-Fluciclovine PET/CT in Multiple Myeloma
Abroad (travel likely)RecruitingPHASE2
Conditions
Multiple Myeloma · Newly Diagnosed Multiple Myeloma (NDMM) · Relapsed and/or Refractory Multiple Myeloma (RRMM)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Contact: Study coordinator (NCI Medical Oncology Referral Office) · ncimo_referrals@nih.gov · 240-760-6050
Study leads
Elizabeth M Hill, M.D.
Principal Investigator
National Cancer Institute (NCI)